7 Undervalued Biotechnology Stocks for Thursday, November 07
Discover the top 7 undervalued Biotechnology stocks for Thursday, November 07 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Aneeqa Nadeem
Jenna Brashear
Eunice Kim
Grace Malone
Jack Gilleland
| Share Statistics | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.8 | $202.9 | 7% |
|
| Shares Out (Mil) | 11.7 | 55.4 | 23% |
|
| Institutional Ownership | 73.5% | 92.9% | 44% |
|
| Float (Mil) | 11.5 | 40.7 | 21% |
|
| Beta | 0.92 | 1.04 | 54% |
|
| Avg Daily Volume (000s) | 76 | 566 | 33% |
|
| Price Change (52-week) |
(48.5%) | 41.0% | 20% |
|
| Growth | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 0.2% | (10.3%) | 40% |
|
| EPS (5yr) | 62.9% | 15.8% | 96 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (56.7%) | (15.7%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.350) | ($1.410) | ($0.730) | |
| Month Ago EPS | ($0.385) | ($1.445) | ($0.610) | |
| # Rev Up | 1 | 1 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.370) | ($1.420) | ($0.630) | |
| Year/Year Chg | (1.7%) | (3.0%) | na | |
| Financials | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($15) | ($44) | 26% |
|
| EPS (TTM) | ($1.325) | ($1.400) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($34) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | ($1) | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $144 | 4% |
|
| Valuation | PHIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.02 | 1.97 | 27% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (128.6%) | (47.4%) | 4% |
|
| ROE | (159.0%) | (53.5%) | 5% |
|
| Liabilities to Assets | 23.8% | 29.7% | 16% |
|
| F-Score | 1 | 3 | 1% |
|
Phio Pharmaceuticals Corp. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors